Montefiore Medical Center at new york The first international installation of the new BIOMONITOR IV ICM was carried out
Lake Oswego, Ore., June 12, 2023 /PRNewswire/ — BIOTRONIK, a leader in implantable medical device technology, today announced the first global implant of the BIOMONITOR IV implantable cardiac monitor (ICM). The process was carried out by Louis DebussyMD, PhD, Head of the Department of Electrophysiology, Director of Arrhythmia Services and Professor of Medicine at Montefiore Einstein BronxNY This first implant represents the next step in the development of cardiac monitoring technology.
BIOMONITOR IV is a state-of-the-art ICM that combines Biotronic’s SmartECG technology with artificial intelligence* to reduce 98% real episodes by 86%.1. It is also the only ICM capable of detecting premature atrial contractions (PACs) and premature ventricular contractions (PVCs) to provide healthcare professionals with better tools for risk assessment and diagnosis.
“I am very excited about the new algorithm and artificial intelligence of BIOMONITOR IV,” he said. Dr. In discrimination. “The data shows that these new features have the potential to reduce false positive alarms for our patients and allow us to focus on actionable events and achieve more efficient care.”
In addition to advanced artificial intelligence, there are various other benefits for patients and healthcare professionals when using BIOMONITOR IV. Long battery life and wireless connectivity enable seamless data transmission and remote monitoring, reducing frequent in-person clinic visits. BIOTRONIK offers the simplest electronic health record (EHR) data integration capability, which greatly improves clinic workflow.
The launch of BIOMONITOR IV is a testament to BIOTRONIK’s commitment to innovation and improving patient care. The company’s cutting-edge technologies continue to push the boundaries of medical advancements, empowering healthcare professionals and improving the lives of patients worldwide. With this acquisition, BIOTRONIK strengthens its position as a leading player in the field of cardiac monitoring devices by contributing to the development of cardiovascular medicine.
References
* AI algorithm is applied only for AF detection.
1. Data on file. The AF filter standard is set to be the most unique in the home surveillance service center. Reduction is relative to SmartECG performance.
Additional information:
About BIOTRONIK:
as if BIOTRONIKPatient safety is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions of people suffering from cardiovascular disease and chronic pain. We are innovators in developing trusted cardiovascular, vascular and neuromodulation solutions, driven by a single goal to fully align technology with the human body. BIOTRONIK is in the headquarters. Berlin, GermanyAnd represented in more than 100 countries.
To download multimedia, see original content: https://www.prnewswire.com/news-releases/biotronik-announced-first-implant-of-new-implantable-cardiac-monitor-with-artificial-intelligence-targeting-efficiency-in – cardiac-arrhythmias-monitoring-301848638.html
Source BIOTRONIK
[ad_2]